Notice 27 Jun 2025 nih, pharmaceutical, biotechnology, clinical studies, cancer prevention, intellectual property

💉NIH Proposes New Intellectual Property Policy for Cancer Research

The National Cancer Institute, an Institute of the National Institutes of Health, Department of Health and Human Services, Division of Cancer Prevention (DCP) is seeking comments on instituting a standard policy on Intellectual Property (IP) developed by certain funding recipients under NCI DCP funding agreements. This standard policy is entitled "The DIVISION OF CANCER PREVENTION INTELLECTUAL PROPERTY OPTION TO COLLABORATORS (IP Option)." The proposed policy, if finalized, shall apply to entities that conduct DCP-funded clinical studies under funding agreements which involve an NCI collaborator that provides its proprietary agent or technology for the DCP-supported studies where this IP Option is included as a term of applicable existing and future funding agreements.

Learn More
Compliance, Regulatory Requirements 8 Jan 2025 compliance, healthcare, information collection, cdc, cancer prevention